NASDAQ : ADRX
ADARx Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 17 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.90B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.84B |
| Enterprise Value | 1.42B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 15, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 112.06M |
| Shares Outstanding | 112.06M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 7.47% |
| Owned by Institutions (%) | 5.45% |
| Float | 51.97M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 310.91 |
| Forward PS | 368.89 |
| PB Ratio | 17.88 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 242.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 12.98 |
| Quick Ratio | 12.56 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -25.17% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $61,270 |
| Profits Per Employee | -$878,700 |
| Employee Count | 100 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 33.03 |
| Average Volume (20 Days) | 405,697 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.90M |
| Short Previous Month | 1.16M |
| Short % of Shares Out | 1.70% |
| Short % of Float | 3.66% |
| Short Ratio (days to cover) | 2.00 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 6.13M |
| Gross Profit | -83.74M |
| Operating Income | -106.30M |
| Pretax Income | -87.87M |
| Net Income | -87.87M |
| EBITDA | -105.12M |
| EBIT | -106.30M |
| Loss Per Share | -$7.74 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 427.25M |
| Total Debt | 6.90M |
| Net Cash | 420.35M |
| Net Cash Per Share | $3.75 |
| Equity (Book Value) | 106.57M |
| Book Value Per Share | -22.16 |
| Working Capital | 407.53M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -88.32M |
| Capital Expenditures | -1.89M |
| Depreciation & Amortization | 1.18M |
| Net Borrowing | n/a |
| Free Cash Flow | -90.21M |
| FCF Per Share | -$0.81 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -1,734.98% |
| Pretax Margin | -1,434.14% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -47.17% |
| FCF Yield | -4.74% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $34.25 |
| Price Target Difference | 108.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 125.95% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.51 |
| Piotroski F-Score | n/a |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |